Dyadic Expands Global Presence with Participation in Key Industry Events
Dyadic International (NASDAQ: DYAI) has announced its participation in several key industry events worldwide, demonstrating its commitment to global expansion and advancing biomanufacturing. The company will attend the Developing Countries Vaccine Manufacturers Network (DCVMN) Int'l Annual Meeting in São Paulo, Brazil (Oct 16-18, 2024), the World Vaccine Congress Europe in Barcelona (Oct 29-31, 2024), and BIO-Europe in Stockholm, Sweden (Nov 4-6, 2024).
At the World Vaccine Congress Europe, Dyadic will present on 'C1 Technology: Redefining Biomanufacturing for a Healthier Tomorrow' on October 30. The company aims to showcase the scalability, speed, and cost advantages of its proprietary C1 and Dapibus™ technology platforms for producing vaccines, therapeutics, and non-pharmaceutical products. These events provide opportunities for Dyadic to foster collaborations and highlight its innovative approaches in biotechnology.
Dyadic International (NASDAQ: DYAI) ha annunciato la sua partecipazione a diversi eventi chiave del settore in tutto il mondo, dimostrando il suo impegno per l'espansione globale e per l'avanzamento della biomanifattura. L'azienda parteciperà al Network dei produttori di vaccini dei Paesi in via di sviluppo (DCVMN) Incontro Annuale Internazionale a São Paulo, Brasile (16-18 ottobre 2024), al World Vaccine Congress Europe a Barcellona (29-31 ottobre 2024), e al BIO-Europe a Stoccolma, Svezia (4-6 novembre 2024).
Durante il World Vaccine Congress Europe, Dyadic presenterà su 'Tecnologia C1: Ridefinire la biomanifattura per un domani più sano' il 30 ottobre. L'azienda mira a mostrare la scalabilità, la rapidità e i vantaggi in termini di costi delle sue piattaforme tecnologiche proprietarie C1 e Dapibus™ per la produzione di vaccini, terapeutici e prodotti non farmaceutici. Questi eventi offrono opportunità per Dyadic di promuovere collaborazioni e mettere in luce i suoi approcci innovativi nella biotecnologia.
Dyadic International (NASDAQ: DYAI) ha anunciado su participación en varios eventos clave de la industria en todo el mundo, demostrando su compromiso con la expansión global y el avance de la biomanufactura. La empresa asistirá a la Red de Fabricantes de Vacunas de Países en Desarrollo (DCVMN) Reunión Anual Internacional en São Paulo, Brasil (16-18 de octubre de 2024), al Congreso Mundial de Vacunas Europa en Barcelona (29-31 de octubre de 2024), y a BIO-Europe en Estocolmo, Suecia (4-6 de noviembre de 2024).
En el Congreso Mundial de Vacunas Europa, Dyadic presentará sobre 'Tecnología C1: Redefiniendo la biomanufactura para un futuro más saludable' el 30 de octubre. La empresa tiene como objetivo mostrar la escalabilidad, velocidad y ventajas de costo de sus plataformas tecnológicas propietarias C1 y Dapibus™ para la producción de vacunas, terapias y productos no farmacéuticos. Estos eventos brindan oportunidades para que Dyadic fomente colaboraciones y destaque sus enfoques innovadores en biotecnología.
Dyadic International (NASDAQ: DYAI)는 글로벌 확장 및 생물 제조 발전에 대한 헌신을 보여주기 위해 전 세계 여러 주요 산업 행사에 참여할 것이라고 발표했습니다. 이 회사는 브라질 상파울루에서 열리는 개발도상국 백신 제조업체 네트워크(DCVMN) 국제 연례 회의에 참석할 예정입니다 (2024년 10월 16-18일), 바르셀로나에서 열리는 세계 백신 회의 유럽 (2024년 10월 29-31일) 및 스웨덴 스톡홀름에서 BIO-Europe (2024년 11월 4-6일)에서 참석합니다.
세계 백신 회의 유럽에서 Dyadic는 10월 30일 'C1 기술: 더 건강한 내일을 위한 생물 제조 재정의'에 대해 발표할 예정입니다. 이 회사는 백신, 치료제 및 비약물 제품을 생산하기 위한 고유한 C1 및 Dapibus™ 기술 플랫폼의 확장성, 속도 및 비용 이점을 보여주는 것을 목표로 하고 있습니다. 이러한 행사는 Dyadic이 협력을 촉진하고 생명공학에서의 혁신적인 접근 방식을 강조할 수 있는 기회를 제공합니다.
Dyadic International (NASDAQ: DYAI) a annoncé sa participation à plusieurs événements clés de l'industrie à l'échelle mondiale, démontrant son engagement envers l'expansion mondiale et l'avancement de la biomanufacture. L'entreprise participera à la Réunion Annuelle Internationale du Réseau des Fabricants de Vaccins des Pays en Développement (DCVMN) à São Paulo, au Brésil (16-18 octobre 2024), au Congrès Mondial des Vaccins Europe à Barcelone (29-31 octobre 2024), et à BIO-Europe à Stockholm, en Suède (4-6 novembre 2024).
Lors du Congrès Mondial des Vaccins Europe, Dyadic présentera sur 'Technologie C1 : Redéfinir la biomanufacture pour un avenir plus sain' le 30 octobre. L'entreprise vise à mettre en avant l'évolutivité, la rapidité et les avantages en termes de coûts de ses plateformes technologiques propriétaires C1 et Dapibus™ pour la production de vaccins, de thérapies et de produits non pharmaceutiques. Ces événements offrent à Dyadic des occasions de favoriser des collaborations et de mettre en lumière ses approches innovantes en biotechnologie.
Dyadic International (NASDAQ: DYAI) hat seine Teilnahme an mehreren wichtigen Branchenveranstaltungen weltweit angekündigt, was das Engagement des Unternehmens für globale Expansion und die Weiterentwicklung der Bioproduktion demonstriert. Das Unternehmen wird an der Internationalen Jahrestagung des Netzwerks der Impfstoffhersteller in Entwicklungsländern (DCVMN) in São Paulo, Brasilien (16.-18. Oktober 2024), am World Vaccine Congress Europe in Barcelona (29.-31. Oktober 2024) und an der BIO-Europe in Stockholm, Schweden (4.-6. November 2024) teilnehmen.
Beim World Vaccine Congress Europe wird Dyadic am 30. Oktober über 'C1-Technologie: Die Bioproduktion für eine gesündere Zukunft neu definieren' sprechen. Das Unternehmen zielt darauf ab, die Skalierbarkeit, Schnelligkeit und Kostenvorteile seiner proprietären C1- und Dapibus™-Technologieplattformen zur Herstellung von Impfstoffen, Therapeutika und nicht-pharmazeutischen Produkten zu präsentieren. Diese Veranstaltungen bieten Dyadic Möglichkeiten zur Förderung von Kooperationen und zur Hervorhebung seiner innovativen Ansätze in der Biotechnologie.
- Participation in multiple international industry events, expanding global presence
- Opportunity to showcase proprietary C1 and Dapibus™ technology platforms
- Potential for fostering new collaborations in the biotechnology sector
- None.
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications, including food, nutrition, and wellness, today announced its participation in several prominent industry events worldwide.
Developing Countries Vaccine Manufacturers Network (DCVMN) Int'l Annual Meeting 2024
São Paulo, Brazil
Oct 16 – 18, 2024
World Vaccine Congress Europe 2024
Fira de Barcelona Montjuic, Barcelona
Oct 29 – 31, 2024
Presentation:
C1 Technology: Redefining Biomanufacturing for a Healthier Tomorrow- Accelerating the Scalable, Cost-Effective Production & Release of Antigens, Antibodies & Enzymes
Wednesday, October 30, 12:10 PM CET
BIO-Europe
Stockholm, Sweden
Nov 4 – 6, 2024
These events underscore Dyadic’s commitment to expanding its global footprint and advancing its mission to revolutionize biomanufacturing with its proprietary C1 and Dapibus™ technology platforms. Through its participation, Dyadic aims to foster collaborations and highlight the scalability, speed, and cost advantages of its platforms for producing vaccines, therapeutics, and non-pharmaceutical products.
If you would like to schedule a meeting with Dyadic, please contact Sam Closa at Assistant@dyadic.com.
About Dyadic International, Inc.
Dyadic International, Inc. (NASDAQ: DYAI) is a biotechnology company focused on the efficient, large-scale production of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications in food, nutrition, and wellness.
Dyadic’s core technologies revolve around the highly productive, scalable fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Its flagship C1-cell protein production platform, derived from the industrial microorganism C1, is designed to accelerate development, lower production costs, and enhance biologic vaccines and drugs for human and animal health markets at flexible commercial scales.
In addition to the C1 platform, Dyadic has developed the Dapibus™ filamentous fungal-based microbial protein production platform. Dapibus™ enables rapid, large-scale production of low-cost proteins, metabolites, and other biologic products for non-pharmaceutical sectors, including food, nutrition, and wellness. Driven by a commitment to help partners develop effective treatments in both developed and emerging markets, Dyadic is advancing its proprietary microbial platforms. The Company is working on a potential “Adjuvanted, Self-assembling Ferritin Nanoparticle H5-2.3.4.4b A/Astrakhan Subunit Vaccine Candidate” for avian influenza, along with other biologic vaccines, antibodies, and related products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit www.dyadic.com
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) competition, including from alternative technologies; (iv) the results of nonclinical studies and clinical trials; (v) our capital needs; (vi) changes in global economic and financial conditions; (vii) our reliance on information technology; (viii) our dependence on third parties; (ix) government regulations and environmental, social and governance issues; and (x) intellectual property risks. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Contact:
Dyadic International, Inc.
Ping W. Rawson, Chief Financial Officer
Phone: 561-743-8333 Email: ir@dyadic.com
FAQ
What events will Dyadic International (DYAI) attend in 2024?
What will Dyadic International (DYAI) present at the World Vaccine Congress Europe 2024?
What are the key technology platforms Dyadic International (DYAI) is promoting at these events?
